HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Rocha-Zavaleta, L. Articles by Monroy-Garcia, A. Search for Related Content PubMed PubMed Citation Articles by Rocha-Zavaleta, L. Articles by Monroy-Garcia, A. Agricola Articles by Rocha-Zavaleta, L. Articles by Monroy-Garcia, A.

Detection of antibodies against a human papillomavirus (HPV) type 16 peptide that differentiate high-risk from low-risk HPV-associated low-grade squamous intraepithelial lesions

¹ Department of Molecular Biology and Biotechnology, Institute of Biomedical Research, National University of Mexico, Circuito Escolar S/N, Cd Universitaria, Apdo Postal 70228, DF CP 04510 Mexico City, Mexico
² Laboratory of Immunobiology (L-326), Unit of Research on Cellular Differentiation and Cancer, FES Zaragoza, National University of Mexico, Mexico City, Mexico
³ National Center for Clinics of Dysplasias (CENACLID), General Hospital of Mexico, Mexico City, Mexico
⁴ Unit of Molecular Biomedicine, CINVESTAV, IPN, Mexico City, Mexico

Correspondence
Alberto Monroy-Garcia
albertomon{at}yahoo.com

A nonapeptide (16L1) was derived from the human papillomavirus type 16 (HPV-16) major capsid protein and tested for detection of potential cross-reactive serum IgG and cervical IgA antibodies in low- and high-risk HPV-associated low-grade squamous intraepithelial lesions (LSIL) and cervical cancer patients by ELISA. The IgG response was similar in women with low-risk HPV-associated LSIL and controls (P=0·1). In contrast, more than 90 % of patients with high-risk HPV-associated LSIL were seropositive. Although tumours from cancer patients were all positive for the presence of high-risk HPV DNA, the level of seropositivity decreased significantly in this group (P<0·0001). Cervical IgA antibodies were also detected in a significantly high proportion of women with high-risk HPV-associated LSIL compared with controls. However, the proportion of IgA-positive patients was lower than the proportion of IgG seropositives. In conclusion, the 16L1 peptide appears to be a high-risk type-common epitope that induces cross-reactive antibodies in high-risk, but not low-risk, HPV-associated LSIL patients, allowing differentiation of high- and low-risk infected women at this stage of infection.

This article has been cited by other articles:

				M. Urquiza, R. Sanchez, J. Amaya, S. Leon, J. Acosta, M. A. Patarroyo, M. Camargo, and M. E. Patarroyo Specificity of L1 Peptides versus Virus-Like Particles for Detection of Human Papillomavirus-Positive Cervical Lesions in Females Attending Engativa Hospital, Bogota, Colombia J. Clin. Microbiol., November 1, 2008; 46(11): 3714 - 3720. [Abstract] [Full Text] [PDF]